Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 13/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 12/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 0.70 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.70 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18569404 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL22838355 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL8383142 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL14089349 | 0.88 | OPRD1 (0.78) | OPRM1OPRD1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL30199760 | 0.85 | OPRM1 (1.00) | OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL21008992 | 0.85 | OPRM1 (1.00) | OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL18569385 | 0.85 | OPRM1 (1.00) | OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL19235930 | 0.84 | OPRM1 (0.73) | OPRM1OPRD1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL24599520 | 0.83 | OPRD1 (1.00) | OPRM1OPRD1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13154676 | 0.83 | OPRD1 (1.00) | OPRM1OPRD1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101951921-A | Be used for the treatment of cachectic ways and means | BIONERIS AB | 2011-01-19 | — | — | CN | claimed |
| WO-2007044229-A2 | SURFACE TREATMENTS FOR CALCIUM PHOSPHATE-BASED IMPLANTS | CALCITEC, INC. (US) | 2007-04-19 | — | — | WO | claimed |
| US-11560578-B2 | Neopinone isomerase and methods of using | ANTHEIA, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11419961-B2 | Bone induction system and methods | VIVEX BIOLOGICS GROUP, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210087596-A1 | METHODS OF PRODUCING NOR-OPIOID AND NAL-OPIOID BENZYLISOQUINOLINE ALKALOIDS | HERCULES CAPITAL, INC., AS AGENT | 2021-03-25 | — | — | US | disclosed |
| US-20200291438-A1 | NEOPINONE ISOMERASE AND METHODS OF USING | HERCULES CAPITAL, INC., AS AGENT | 2020-09-17 | — | — | US | disclosed |
| US-10738335-B2 | Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids | ANTHEIA, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190321516-A1 | BONE INDUCTION SYSTEM AND METHODS | VIVEX BIOLOGICS GROUP, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10434217-B2 | Bone induction system and methods | VIVEX BIOLOGICS GROUP, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190144900-A1 | METHODS OF PRODUCING NOR-OPIOID AND NAL-OPIOID BENZYLISOQUINOLINE ALKALOIDS | HERCULES CAPITAL, INC., AS AGENT | 2019-05-16 | — | — | US | disclosed |
| EP-3122269-A1 | ARTIFICIAL SKELETAL MATERIAL AND CONSTRUCTS FORMED THEREFROM | Cormatrix Cardiovascular, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2001495-A2 | METHODS FOR REGULATING NEUROTRANSMITTER SYSTEMS BY INDUCING COUNTERADAPTATIONS | Michalow, Alexander (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20080045610-A1 | Methods for regulating neurotransmitter systems by inducing counteradaptations | MICHALOW ALEXANDER | 2008-02-21 | — | — | US | disclosed |
| US-20070213827-A1 | Hardened calcium phosphate cement bone implants | CALCITEC, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213832-A1 | Surface treatments for calcium phosphate-based implants | CALCITEC, INC. | 2007-09-13 | — | — | US | disclosed |
| WO-2007100775-A2 | METHODS FOR REGULATING NEUROTRANSMITTER SYSTEMS BY INDUCING COUNTERADAPTATIONS | MICHALOW ALEXANDER (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007044229-A2 | SURFACE TREATMENTS FOR CALCIUM PHOSPHATE-BASED IMPLANTS | CALCITEC, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007038559-A2 | HARDENED CALCIUM PHOSPHATE CEMENT BONE IMPLANTS | CALCITEC, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
| US-6913760-B2 | Drug delivery composition | NEW ENGLAND MEDICAL HOSPITALS, INC. (US) | 2005-07-05 | — | — | US | disclosed |
| US-20030170288-A1 | Drug delivery composition | US GOVERNMENT - SECRETARY FOR THE ARMY | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045610-A1 | Methods for regulating neurotransmitter systems by inducing counteradaptations | HTR5A, NTSR2, SLC6A2 | OPRM1 128/4885OPRD1 114/4885OPRK1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.